Long-term real-life outcomes of the Clareon® hydrophobic intraocular lens: the Clarte study in 191 eyes

Background To describe and analyze the real-life refractive, functional and safety outcomes of the Clareon (R) intraocular lens (IOL) after 3 years.Methods Data was collected retrospectively for observational purposes between July 2017 and December 2019 in the ophthalmology department of Desgenettes military hospital in Lyon, France. Eyes that underwent cataract surgery with Claeron (R) implantation were consecutively included. Patients with a systemic or ocular condition that could affect the visual outcome were excluded. Postoperative corrected (CDVA) and uncorrected (UDVA) distance visual acuities as well as capsule and IOL transparency were assessed at 1 month and 3 years.Results A total of 326 eyes were analyzed at one month and 191 eyes were reassessed at the 3-year follow-up visit. At 3 years, the mean CDVA was 0.003 LogMAR (95% confidence interval [CI]: -0.003 to -0.01) and the mean UDVA was 0.075 (95% CI: 0.054 to 0.095). Three quarters of the patients had an UDVA >= 0.097 logMAR (20/25 Snellen equivalent) and 50% had an UDVA >= 0 (20/20). The absence of glistening was reported in 95.3% of cases and 4.7% [9] of patients experienced a clinically significant posterior capsular opacification (PCO) for which Nd:YAG treatment was required.Conclusions This real-life study reports high-performance and stable long-term refractive outcomes of the Clareon (R) IOL with good safety in terms of PCO and glistening. What is knownThe Clareon (R) is a recent hydrophobic intraocular lens (IOL) that has shown high-performance functional and safety outcomes in published studies after a 1-year follow-up.What is newThese good functional and safety outcomes were maintained over a 3-year follow-up.A low rate of Nd:YAG treatment was reported (4.7%), and it was needed late during the third year following surgery. This finding is comparable with what has been reported with the AcrySof material.A low rate of glistening over time was confirmed.